Examining three frailty conceptualizations in their ability to predict negative outcomes for home-care clients.

439–44. 14. Sharma JC, Ananda K, Ross I, Hill R, Vassallo M. N-terminal proBrain natriuretic peptide levels predict short-term poststroke survival. J Stroke Cerebrovasc Dis 2006; 15: 121–7. 15. Etgen T, Baum H, Sander K, Sander D. Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke 2005; 36: 270–5. 16. Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the Modified Rankin Scale. A systematic review. Stroke. Published online ahead of print 13 August 2009. 17. Anand IS, Fisher LD, Chiang YT et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278–83. 18. Cowie MR, Mendez GF. BNP and congestive cardiac failure. Prog Cardiovasc Dis 2002; 44: 293–321. 19. Jensen JK, Atar D, Kristensen SR, Mickley H, Januzzi JL Jr. Usefulness of natriuretic peptide testing for long-term risk assessment following acute ischemic stroke. Am J Cardiol 2009; 104: 287–91. 20. Nogami M, Shiga J, Takatsu A, Endo N, Ishiyama I. Immunohistochemistry of atrial natriuretic peptide in brain infarction. Histochem J 2001; 33: 87–90. 21. Sviri GE, Shik V, Raz B, Soustiel JF. Role of brain natriuretic peptide in cerebral vasospasm. Acta Neurochir (Wien) 2003; 145: 851–60. 22. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330: 625.